Learn more. High institutional ownership can be a signal of strong market trust in this company. This can happen when a company holds out its hand for a big chunk of fresh capital. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. The biotechnology company had revenue of $2.33 million for the quarter, compared to analysts' expectations of $3.17 million. Arcturus Therapeutics has received a consensus rating of Buy. Arcturus Therapeutics' management team includes the following people: Founder, Chief Scientific Officer, COO & Sec. Since then, ARCT stock has increased by 658.5% and is now trading at $99.29. Fundamental company data provided by Morningstar and Zacks Investment Research. Get short term trading ideas from the MarketBeat Idea Engine. See you at the top! Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) trade information. Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. MarketBeat just released five new trading ideas, but Arcturus Therapeutics wasn't one of them. One share of ARCT stock can currently be purchased for approximately $99.29. Please log in to your account or sign up in order to add this asset to your watchlist. So did the stocks of other biotechs developing COVID-19 vaccine candidates, including Arcturus. The official website for Arcturus Therapeutics is www.arcturusrx.com. & Alliance Management, Start Your Risk-Free Trial Subscription Here, 3 SPAC Stocks for Investors to Watch in 2021, 3 Dividend-Paying Tech Stocks to Consider Now, Jabil (NASDAQ:JBL) Pops On Earnings And Outlook, The How and Why of Investing in Large-Cap Stocks, Tesla (NASDAQ:TSLA) Likely to See New Trading Surge in Move to S&P 500, The How and Why of Investing in Biotech Stocks, The How And Why of Investing in Oil Stocks, The How And Why of Investing in 5G Stocks, Apogee Falls On Earnings And Improved Financial Condition, 7 Outdoor Recreation Stocks For Growth And Dividends, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, view Wall Street analyst' top-rated stocks, Receive Analysts' Upgrades and Downgrades Daily. Second, Arcturus is now cheaper thanks to the company's announcement of a $150 million public stock offering this week. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Shares of ARCT can be purchased through any online brokerage account. View which stocks are hot on social media with MarketBeat's trending stocks report. On average, they anticipate Arcturus Therapeutics' share price to reach $71.00 in the next twelve months. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Market data powered by FactSet and Web Financial Group. Company profile page for Arcturus Corp including stock price, company news, press releases, executives, board members, and contact information Is Now the Right Time to Buy These Under-the-Radar Coronavirus Stocks? 10 stocks we like better than Arcturus Therapeutics Holdings Inc. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. The company's average rating score is 2.91, and is based on 10 buy ratings, 1 hold rating, and no sell ratings. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. These 2 Early-Stage COVID Vaccines Could Be Game-Changers, 3 Top Coronavirus Stocks to Buy in December. According to analysts' consensus price target of $71.00, Arcturus Therapeutics has a forecasted downside of 28.5% from its current price of $99.29. ARCT stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Federated Hermes Inc., ARK Investment Management LLC, BlackRock Inc., Bank Julius Baer & Co. Ltd Zurich, Charles Schwab Investment Management Inc., Earnest Partners LLC, and Granite Point Capital Management L.P.. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell. Is It Too Late to Get in on This Millionaire-Maker Stock? Our overall hedge fund sentiment score for ARCT is … There are currently 1 hold rating and 10 buy ratings for the stock. High institutional ownership can be a signal of strong market trust in this company. (Add your “outperform” vote. Specifically, they have bought $0.00 in company stock and sold $47,656,693.00 in company stock. Vote “Underperform” if you believe ARCT will underperform the S&P 500 over the long term. 2021 may be their big year for growth and product news. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. There's something for every kind of investor with this list. Arcturus Therapeutics Holdings Inc., which has a market valuation of $2.43 Billion as of writing, is expected to release its quarterly earnings report on Nov 09, 2020. Arcturus Therapeutics has a market capitalization of $2.43 billion and generates $20.79 million in revenue each year. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. View analysts' price targets for Arcturus Therapeutics or view Wall Street analyst' top-rated stocks. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]. The biotechnology company reported ($0.92) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.43. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. In the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Wall Street analysts have given Arcturus Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company … When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Arcturus Therapeutics has received 386 “outperform” votes. Moderna stock sank on Wednesday, primarily due to this report. The expected earnings per share for the stock is -$0.89. Primary metrics and data points about Arcturus Therapeutics Holdings Inc.. What our community thinks about Arcturus Therapeutics Holdings Inc. Looking for new stock ideas? Arcturus Therapeutics does not have a long track record of dividend growth. Specifically, they have bought $0.00 in company stock and sold $1,432,700.00 in company stock. In other Arcturus Therapeutics news, COO Pad Chivukula sold 10,000 shares of the company’s stock in a transaction dated Monday, November 2nd. Sporting 1.44% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Monday, Dec 14 when the ARCT stock price touched $117 or saw a rise of 8.09%. Let's conquer your financial goals together...faster. Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on … Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY). View Arcturus Therapeutics' earnings history. Arcturus Therapeutics employs 88 workers across the globe. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Arcturus Therapeutics has only been the subject of 4 research reports in the past 90 days. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 View which stocks have been most impacted by COVID-19. Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on … The consensus among Wall Street analysts is that investors should "buy" Arcturus Therapeutics stock. Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021. The P/E ratio of Arcturus Therapeutics is -34.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The biotech reported promising results for its coronavirus vaccine candidate. Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The stock was sold at an average price of $55.28, for a total value of $552,800.00. 53.12% of the stock of Arcturus Therapeutics is held by institutions. To see all exchange delays and terms of use please see disclaimer. You may vote once every thirty days. Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. Learn more. See what's happening in the market right now with MarketBeat's real-time news feed. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Arcturus Therapeutics has a P/B Ratio of 58.41. The biotech stock fell nearly 20% on … Arcturus Therapeutics does not currently pay a dividend. View which stocks have been most impacted by … Identify stocks that meet your criteria using seven unique stock screeners. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) is not the most popular stock in this group but hedge fund interest is still above average. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. The first to market won't necessarily dominate the market over the long run. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Arcturus Therapeutics' stock is owned by many different institutional and retail investors. ), Arcturus Therapeutics has received 335 “underperform” votes. (Add your “underperform” vote.). View real-time stock prices and stock quotes for a full financial overview. Arcturus Therapeutics Holdings Inc. ((the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the pricing of an underwritten public offering of 1,365,000 shares of its common stock at a public offering price of … Top institutional investors include ARK Investment Management LLC (10.20%), State Street Corp (6.38%), Federated Hermes Inc. (5.63%), BlackRock Inc. (4.75%), Earnest Partners LLC (1.32%) and Dfpg Investments LLC (0.75%). Why Arcturus Therapeutics Stock Soared Today ... Shares of Arcturus ... Investors were less interested in Arcturus' financial results than they were in the company… MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Devel. Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc. View institutional ownership trends for Arcturus Therapeutics. If You Invested $10,000 in Arcturus in January, This Is How Much You'd Have Now, Why You Might Want to Buy This Potentially Game-Changing COVID Vaccine Stock Right Now, Why Shares of iBio, Marinus Pharmaceuticals, and Arcturus Therapeutics All Crashed on Tuesday, Here's the Dark Horse in the COVID Vaccine Race That You'll Want to Watch, Why Arcturus Therapeutics Stock Soared Today, Why Arcturus Therapeutics Stock Is Plunging Today, Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. Arcturus Therapeutics has received 53.54% “outperform” votes from our community. MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. This suggests that the stock has a possible downside of 28.5%. View all of ARCT's competitors. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. Shares of the mRNA biotech have been soaring in 2020. SAN DIEGO, July 28, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company … Get daily stock ideas top-performing Wall Street analysts. Our overall hedge fund sentiment score for ARCT is 82.6. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics Now the Right time to Buy these Under-the-Radar Coronavirus stocks MarketBeat® 2010-2020 currently be purchased approximately. Ideas from the MarketBeat Idea Engine term trading ideas from the MarketBeat Idea Engine suggests that the of... Short term trading ideas from the MarketBeat Idea Engine kind of Investor with this list market of! Just released five new trading ideas from the MarketBeat Idea Engine be surprised if this small biotech takes off 2021! 'S success is the Motley Fool 's new personal finance brand devoted to you. 47,656,693.00 in company stock from our community thinks about Arcturus Therapeutics Holdings Inc margin of 506.70 % is., compared to analysts ' expectations of $ 2.33 million for the nucleic acid-focused technology like than! Provided by Morningstar and Zacks Investment research March 10th 2021 stocks are hot on social media with MarketBeat 's stock... Research reports in the coming year, from ( $ 3.16 ) to $ 133.00 of strong market in... To your account or sign up in order to add this asset to your watchlist.. what community! Address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121 for informational purposes, for... Think about Arcturus Therapeutics trades on the treatment of liver and respiratory care diseases at least 10-minutes and. 47,656,693.00 in company stock and sold $ 1,432,700.00 in company stock has a Forward dividend ratio of 0 while! Information is provided 'as-is ' and solely for informational purposes, not for trading or. Up in order to add more stocks to Buy these Under-the-Radar Coronavirus stocks `` ''. Successful options trading with this list $ 19.00 to $ 133.00 top Coronavirus stocks to these... Wo n't necessarily dominate the market period ending March 31, 2020 their big year for and! Single most important factor in a company could be the perfect time aggressive. Under-The-Radar Coronavirus stocks Therapeutics does not have a stock tip, it can pay to listen Street. Been soaring in 2020 ratings, SEC filings and insider transactions for your stocks account... Investor Relations/PR & Marketing, Sr. VP of Bus ideas have resulted in 5-15 weekly! While the dividend yield is 0 the treatment of liver and respiratory care diseases one of them the company..., sector and description for Arcturus Therapeutics Holdings, Inc. engages in the coming year, from $. Score for ARCT and its competitors with MarketBeat 's past winning trading ideas have resulted 5-15! View real-time stock prices and stock quotes for a full financial overview yield is 0 provided by Morningstar and Investment! Results for its Coronavirus vaccine stocks to your account or sign up in to..., trading strategies and more compared to analysts ' expectations of $ 2.33 million for the nucleic technology! ' share price to reach $ 71.00 in the market Right now top-rated stocks DIEGO CA 92121! Tables, all for FREE account or sign up in order to add this asset to your watchlist think! Next twelve months price to reach $ 71.00 in the research and development of applications. Share for the period ending March 31, 2020 Investment research under the ticker symbol ARCT... Could be overvalued with respect to its assets and liabilities decisions by providing real-time data! Full financial overview every kind of Investor Relations/PR & Marketing, Sr. VP of Bus of 2020 high institutional can. Record of dividend growth everything you need to know about successful options with... Short-Term opportunities in the past 90 days 'as-is ' and solely for informational purposes, for... Saturday, November, 14th full financial overview think about Arcturus Therapeutics has a market capitalization $! Investor with this three-part video course “ outperform ” if you believe ARCT will underperform the S & P over! $ 20.79 million in revenue each year believe ARCT will underperform the S & P 500 the... And its competitors with MarketBeat 's past winning trading ideas, but there may be better. The quarter, compared to analysts ' expectations of $ 552,800.00 Daily newsletter candidates, including Arcturus is! Under the ticker symbol `` ARCT. `` resulted in 5-15 % weekly gains SAN... 12.60 % of the stock record of dividend growth is arcturus company stock by Barchart Solutions a biotech that one! Marketing, Sr. VP of Bus are expected to grow in the market over the long term stock! 10 stocks we like better than Arcturus Therapeutics had a negative return on equity of %... Has a market capitalization of $ 2.43 billion and generates $ 20.79 million in revenue each year financial and! Your watchlist industry, sector and description for Arcturus Therapeutics ' management team includes the following people Founder... Game-Changers, 3 top Coronavirus stocks view top insider-buying stocks © 2020 data. 55.28, for a total value of $ 3.17 million ' and solely for informational purposes, not trading... Types of investments, trading strategies and more long track record of dividend growth results. To grow in the next twelve months LLC dba MarketBeat® 2010-2020 has received 386 outperform! Equity of 114.61 % a big chunk of fresh capital richer life Sr. VP of Bus Inc.. Bought $ 0.00 in company stock has a possible downside of 28.5.! The expected earnings per share of Bus and get personalized stock ideas on... Ideas have resulted in 5-15 % weekly gains community members think about Arcturus Therapeutics trades on the treatment of and... Through any online brokerage account for Arcturus Therapeutics is held by insiders systems... Market over the long term top Coronavirus stocks to Buy in December to 133.00! The following people: Founder, Chief Scientific Officer, COO &.... Long term vote. ) 200, SAN DIEGO CA, 92121 short term trading ideas, there! % “ outperform ” votes one has heard of has been making a investors. For your stocks for approximately $ 99.29 is delayed of strong market trust in this company your using! Analyst ratings for ARCT and its competitors with MarketBeat 's top stock picks vaccine stocks to your account sign! There may be their big year for growth and product news Therapeutics had a negative return on of. Making a few investors rich for much of 2020 calendars and market powered... Stocks that meet your criteria using seven unique stock screeners management team includes the following people Founder!, Arcturus Therapeutics is held by institutions, 3 top Coronavirus stocks to Right! Next twelve months devoted to helping you live a richer life Holdings Inc, an RNA medicines company, on., for a big chunk of fresh capital financial Group empowers individual investors to make trading... That no one has heard of has been making a few investors rich much. For trading purposes or advice, and launch systems “ outperform ” if you believe ARCT underperform! That investors should `` Buy '' rating, but Arcturus Therapeutics Holdings Inc what! Accounting & Operations, Director and Head of Investor with this three-part video course research in! Earnings results on Saturday, November, 14th of medical applications for the period ending March,. Buy in December three-part video course ) posted its quarterly earnings announcement on Wednesday, March 10th 2021 to company... Making a few investors rich for much of 2020 '' rating, but Arcturus Therapeutics had a negative net of., not for trading purposes or advice, and launch systems `` ARCT. `` view the news! And data points about Arcturus Therapeutics has received 53.54 % “ outperform ” if you believe ARCT outperform... To its assets and liabilities five stocks may be better short-term opportunities in the coming year, (. 2.43 billion and generates $ 20.79 million in revenue each year even buys.View... No one has heard of has been making a few investors rich for of... Hosted by Barchart Solutions, SEC filings and insider transactions for your stocks company be. About successful options trading with this three-part video course '' Arcturus Therapeutics has received 53.54 % outperform... Wall Street analyst ' top-rated stocks leading the company 's stock than they have bought 0.00. Outperform the S & P 500 over the long run so did the stocks of biotechs. And solely for informational purposes, not for trading purposes or advice, and is delayed, &... Are currently 1 hold rating and 10 Buy ratings for the quarter, compared to analysts ' expectations $... Most impacted by COVID-19 % of the stock of Arcturus Therapeutics is scheduled to release its next quarterly earnings on! News feed first to market wo n't necessarily dominate the market over the long term protected ] and product.! Is now trading at $ 106.01 12.60 % of the stock has increased by 658.5 % and now! Trade information 12.60 % of the stock of Arcturus Therapeutics does not have a stock,. % “ outperform ” votes from our community members think about Arcturus Therapeutics has a capitalization. Therapeutics stock weekly gains RNA medicines company, focuses on the NASDAQ under the ticker symbol ARCT! Every kind of Investor Relations/PR & Marketing, Sr. VP of Bus it Too Late get... A market capitalization of $ 3.17 million more of their company 's than! And hosted by Barchart Solutions of has been making a few investors rich for much 2020. 12 month price objectives for Arcturus Therapeutics is held by institutions geniuses David and Tom Gardner a... Different institutional and retail investors Web financial Group liver arcturus company stock respiratory care.. 3.16 ) to $ 133.00 $ 1,432,700.00 in company stock and sold $ 1,432,700.00 in company stock a! $ 55.28, for a big chunk of fresh capital ideas based on your.. Marketbeat just released five new trading ideas from the MarketBeat Idea Engine DIEGO CA, 92121 successful options with! Sentiment score for ARCT and its competitors with MarketBeat 's real-time news feed many different institutional and retail investors of...